Skip to content
Head to head

Regencell Bioscience vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: RGC · TAK

Updated 5 minutes ago

1-year performance, rebased to 100

RGC -67.7%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
RGCTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price4.1821.77
Change today-4.13%+1.68%
1-year return-66.9%+57.5%
Market cap$2.07B$69.76B
52-week range4.12 – 69.0013.92 – 22.07
Valuation
P/E (TTM)-174.17311.00
P/E percentile, own 5-yr range41st100th
P/B154.811.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.02-0.30
Net profit (TTM)$-11.90M$-970.94M
Revenue (TTM)$3.16B$4.69T
Provider revenue period date2017-12-302026-09-29
Revenue growth (YoY)+6.0%+6.7%
Gross margin62.3%65.8%
Operating margin8.6%14.3%
Net margin3.6%0.9%
Free cash flow (TTM)$159.50M$433.95B
Provider cash-flow period date2017-12-302026-09-29
Ownership & sentiment
Institutional ownership0.3%51.3%
Insider activity (12mo)0 buy / 2 sell19 buy / 31 sell
Short interest (% of float)0.1%0.1%
Analyst consensus--100% buy (1)
Analyst price target--$50 (+132%)
StockVane view
StockVane Quant RatingE (2)C (90)
Company
Employees1047,029
Founded20141781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.